Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 14Unknown 9Recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 1

Conditions

Leukemia, Prolymphocytic, T-Cell 1

Interventions

Cyclophosphamide 30Rituximab 23zanubrutinib 18fludarabine 14Vincristine 14venetoclax 13Prednisone 13blinatumomab 12Magnetic Resonance Spectroscopy 12Specimen Handling 11Doxorubicin 11obinutuzumab 10Bendamustine Hydrochloride 10Lenalidomide 9Dexamethasone 8polatuzumab vedotin 7glofitamab 7Methotrexate 7Radiotherapy 6Prednisolone 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Cytarabine 6Biopsy 6pirtobrutinib 5pegaspargase 5Immunotherapy, Adoptive 5tislelizumab 4tafasitamab 4selinexor 4orelabrutinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Cladribine × Lymphoid × Clear all
NCT07311746 2025-12-31

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
36 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Prolymphocytic, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡